You are here: Home: BCU CME | 2005: Faculty disclosures
 
     
 

CONTENT VALIDATION AND DISCLOSURES

Research To Practice is committed to providing its participants with high-quality, unbiased and state-of- the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content validation process. The content of each activity is reviewed by both a member of the scientific staff and an external independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

The scientific staff and consultants for Research To Practice are involved in the development and review of content for educational activities and report the following real or apparent conflicts of interest for themselves (or their spouses/partners) that have been resolved through a peer review process: Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD and Kathryn Ault Ziel, PhD — no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc, AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche Laboratories Inc and Sanofi- Aventis, who have no influence on the content development of our educational activities.

In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts of interest that have been resolved through a peer review process:

Dr Budd — Grants/Research Support: AstraZeneca Pharmaceuticals LP, Immunicon Corporation, Novartis Pharmaceuticals, Pfizer Inc, Sanofi-Aventis, Wyeth; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Novartis Pharmaceuticals, Pfizer Inc, Sanofi-Aventis. Dr Buzdar — Grants/Research Support: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Pfizer Inc, Roche Laboratories Inc, TAIHO Pharmaceutical Co Ltd; Honoraria: AstraZeneca Pharmaceuticals LP, Pfizer Inc. Dr Chang — Grants/Research Support: Genentech BioOncology, Sanofi-Aventis. Dr Chlebowski — Grants/Research Support: Amgen Inc, Pfizer Inc; Consulting Fees and Other Financial/Material Support: AstraZeneca Pharmaceuticals LP, Eli Lilly and Company, Novartis Pharmaceuticals, Organon, Pfizer Inc, Sanofi-Aventis. Dr Gradishar — Grants/Research Support: Abraxis Oncology, AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals, Sanofi-Aventis; Consultant and Honoraria: Amgen Inc, GlaxoSmithKline, Roche Laboratories Inc. Dr Hayes — Grants/Research Support: GlaxoSmithKline, Immunicon Corporation, Wyeth; Consultant and Honoraria: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Dendreon, Genomic Health Inc, Immunicon Corporation, Novartis Pharmaceuticals, Pfizer Inc, Precision Therapeutics Inc, Roche Laboratories Inc, Sanofi-Aventis, Wyeth. Dr Mackey — Grants/ Research Support and Honoraria: Amgen Inc, AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals, Roche Laboratories Inc, Sanofi-Aventis; Consultant: Sanofi-Aventis. Dr Miller — Grants/Research Support: GlaxoSmithKline, Medarex Inc, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Osborne — Grants/Research Support: AstraZeneca Pharmaceuticals LP, Merck and Company Inc; Consultant and Honoraria: AstraZeneca Pharmaceuticals LP, Novartis Pharmaceuticals, Pfizer Inc, Merck and Company Inc. Dr Ravdin — Grants/Research Support: AstraZeneca Pharmaceuticals LP; Consultant: Pfizer Inc, Sanofi-Aventis; Ownership: Adjuvant! Inc. Dr Seidman — Consultant: Cephalon Inc, Pharmion Corporation, Sonus Pharmaceuticals Inc, Taxolog Inc; Honoraria and Speakers Bureau: Abraxis Oncology, Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis Pharmaceuticals, Pfizer Inc, Sanofi-Aventis. Dr Vogel — Grants/Research Support: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, TAIHO Pharmaceutical Co Ltd; Honoraria and Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Biomira Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, EMD Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis. Dr Winer — Grants/Research Support: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc; Honorarium: Genentech BioOncology.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

G Thomas Budd, MD
Professor of Medicine
Cleveland Clinic
Lerner College of Medicine of
Case Western Reserve University
Cleveland Clinic Foundation
Cleveland, Ohio


Aman U Buzdar, MD
Professor of Medicine
Deputy Chairman, Department of
Breast Medical Oncology
The University of Texas
MD Anderson Cancer Center
Houston, Texas


Jenny C Chang, MD
Associate Professor
Breast Center at
Baylor College of Medicine
Houston, Texas


Rowan T Chlebowski, MD, PhD
Professor of Medicine
David Geffen School of Medicine at UCLA
Chief, Medical Oncology
Harbor-UCLA Medical Center
Torrance, California


William J Gradishar, MD
Director, Breast Medical Oncology
Associate Professor of Medicine
Robert H Lurie Comprehensive
Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois


Daniel F Hayes, MD
Professor of Internal Medicine
Clinical Director, Breast Oncology Program
Division of Hematology/Oncology
Department of Internal Medicine
University of Michigan
Comprehensive Cancer Center
Ann Arbor, Michigan

John Mackey, MD
Medical Oncologist, Cross Cancer Institute
Associate Professor
Medical and Experimental Oncology
University of Alberta
Chair, Northern Alberta
Breast Cancer Program
Canadian Leader, Breast Cancer
International Research Group
Edmonton, Canada


Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Associate Professor of Medicine
Department of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana


C Kent Osborne, MD
Director, Cancer Center
Professor of Medicine and
Molecular and Cellular Biology
Baylor College of Medicine
Houston, Texas


Peter M Ravdin, MD, PhD
Clinical Professor of Medicine
The University of Texas
Health Science Center at San Antonio
San Antonio, Texas


Andrew D Seidman, MD
Associate Attending Physician
Breast Cancer Medicine Service
Memorial Sloan-Kettering Cancer Center
New York, New York


Charles L Vogel, MD
Medical Director
Cancer Research Network Inc
Plantation, Florida


Eric P Winer, MD
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

 


  
 
 
     
 
 


 
Editor’s Note:
Common questions about breast cancer from oncologists in community practice


Case 1: An active 79-year-old woman with a 7.5-centimeter, Grade II, ER/PR-positive, HER2-negative breast cancer with lymphovascular invasion and three positive nodes (from the practice of Dr Martha A Tracy)
- Select publications

Case 2: A 41-year-old premenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma and six positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 3: A 68-year-old woman with disease progression 10 years after presenting with hormone receptor-positive diffuse metastatic disease to the bone (from the practice of Dr Ghaleb A Saab)
- Select publications

Case 4: A 91-year-old woman with dementia who was diagnosed with Stage II, ER-positive, lymph node-negative breast cancer 15 years ago and now has diffuse bone metastases (from the practice of Dr Juliann M Smith)
- Select publications

Case 5: A 41-year-old surgically postmenopausal woman with a 3.5-centimeter, ER/PR-positive, HER2-positive tumor and two positive lymph nodes (from the practice of Dr Herbert I Rappaport)
- Select publications

Case 6: A 45-year-old premenopausal woman with a 0.7-cm, ER/PR-positive, HER2-positive tumor with 25 percent high-grade DCIS and an Oncotype DX™ recurrence score of 16 (from the practice of Dr Steven W Papish)
- Select publications

Case 7: A woman who presented in 1989 with an infiltrating lobular carcinoma and 21 positive nodes and was treated with adjuvant chemotherapy and tamoxifen and then develops metastatic disease and is treated over the next 11 years with a variety of chemotherapeutic and hormonal agents (from the practice of Dr Pamela Drullinsky)
- Select publications

Case 8: A 35-year-old woman with a 3.5-cm, ER/PR-positive, HER2-positive infiltrating ductal carcinoma and two positive sentinel lymph nodes treated on the nontrastuzumab- containing arm of the Intergroup N9831 trial (from the practice of Dr Pamela Drullinsky)
- Select publications
 
CME Information
Faculty Disclosures
Editor's Office